Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category, whereas...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual Electrophysiology for the Diagnosis of Glaucoma: A Report by the American Academy of Ophthalmology.

Ophthalmology·2026
Same author

Inflammatory Mediators in Diabetic Macular Edema: A Prospective, Controlled Study.

Retina (Philadelphia, Pa.)·2026
Same author

Broadband Access and Ophthalmologist Density in the United States: Cross-Sectional Questionnaire Study.

JMIR public health and surveillance·2026
Same author

Advances in Gene Therapy for Age-Related Macular Degeneration: A Narrative Review.

Journal of clinical medicine·2026
Same author

A Single-Center Analysis of Variables Used to Select a Vitreoretinal Surgery Training Program.

Journal of vitreoretinal diseases·2026
Same author

Diagnosis in the digital age.

Families, systems & health : the journal of collaborative family healthcare·2026
Same journal

Preface.

Handbook of clinical neurology·2026
Same journal

Foreword.

Handbook of clinical neurology·2026
Same journal

Fundus autofluorescence imaging.

Handbook of clinical neurology·2026
Same journal

The electroretinogram as a means to study the physiology of the retina.

Handbook of clinical neurology·2026
Same journal

Adaptive optics scanning light ophthalmoscopy.

Handbook of clinical neurology·2026
Same journal

Modeling the human retina in a dish: Advances and future directions.

Handbook of clinical neurology·2026
See all related articles

Related Experiment Video

Updated: Jun 1, 2026

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

Retinal vein occlusion.

Tahreem A Mir1, Ingrid U Scott2, Stephen J Kim3

  • 1Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa, Iowa City, IA, United States.

Handbook of Clinical Neurology
|May 30, 2026
PubMed
Summary
This summary is machine-generated.

Retinal vein occlusion (RVO) is a common cause of vision loss. Advances in anti-VEGF treatments have improved outcomes, but long-term, durable options are still needed for this chronic condition.

Keywords:
Antivascular endothelial growth factorBranch retinal vein occlusionCentral retinal vein occlusionHemiretinal vein occlusionIntravitreal steroidsMacular edemaNonperfusion

More Related Videos

In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility
07:35

In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility

Published on: April 21, 2022

Related Experiment Videos

Last Updated: Jun 1, 2026

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility
07:35

In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility

Published on: April 21, 2022

Area of Science:

  • Ophthalmology
  • Retinal Vascular Diseases

Background:

  • Retinal vein occlusion (RVO) is the second most common retinal vascular disease.
  • It can lead to significant vision loss, primarily due to macular edema, hemorrhages, and ischemia.
  • Recent advancements in imaging and anti-VEGF therapies have improved RVO management.

Purpose of the Study:

  • To review the current diagnostic and therapeutic strategies for RVO.
  • To highlight the efficacy of anti-VEGF agents as first-line treatment for macular edema.
  • To discuss the role of other treatments and the need for long-term solutions.

Main Methods:

  • Review of current literature on RVO diagnosis and treatment.
  • Analysis of the effectiveness of anti-VEGF agents, intravitreal steroids, and laser photocoagulation.
  • Discussion of treatment strategies for both macular edema and neovascular complications.

Main Results:

  • Anti-VEGF agents are the primary treatment for RVO-associated macular edema, showing significant visual and anatomic improvements.
  • Intravitreal steroids and grid laser photocoagulation serve as second-line options.
  • Panretinal photocoagulation is standard for neovascular complications, often with anti-VEGF as adjunct therapy.

Conclusions:

  • Current treatments have improved RVO outcomes, but it remains a chronic condition requiring ongoing management.
  • Treatment fatigue and loss to follow-up are challenges.
  • There is an ongoing need for more durable, long-term treatment options for RVO, with individualized patient-physician discussion being key.